Covaxin receives approval for emergency use in 12-18 years old children

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children

Hyderabad-based pharmaceutical company, Bharat Biotech has announced that its COVID-19 vaccine Covaxin has received approval for emergency use in 12-18 years old children.

As per company’s statement, “Covaxin is formulated uniquely such that the same dosage can be administered to adults and children.”

“Covaxin has established a proven record for safety and efficacy in adults for the original variant and subsequent variants. We have documented excellent safety and immunogenicity data readouts in children. We look forward for Covaxin to provide similar levels of protection for adults and children alike”, it added.

Bharat Biotech in an official statement thanked Ministry of Health and Family Welfare, DCGI, NITI Aayog and NTAGI for their diligent review of all data and for their fastidious approval process.